Key result
IV lipo-PGE1 linked to clinical response in ~78% of patients with neurogenic intermittent claudication.
Why the study?
Circulation disturbances in the cauda equina and nerve roots have been implicated in neurogenic intermittent claudication in patients with lumbar spinal stenosis, but clinical effects of intravenous lipoprostaglandin E1 treatment were not well established.
Does intravenous lipoprostaglandin E1 improve symptoms in patients with neurogenic intermittent claudication associated with lumbar spinal stenosis?
Observational (n=40)
Does intravenous lipoprostaglandin E1 improve symptoms in patients with neurogenic intermittent claudication associated with lumbar spinal stenosis?
Intravenous lipoprostaglandin E1 provides temporary symptomatic improvement in walking ability and leg numbness for patients with neurogenic intermittent claudication.
Circulation disturbances in the cauda equina and nerve roots have been implicated in the genesis of neurogenic intermittent claudication (NIC) in patients with lumbar spinal stenosis (LSS). We report the clinical results of lipoprostaglandin E1 (lipo-PGE1) treatments in patients with NIC. Lipo-PGE1 was administered intravenously for 10 consecutive days to 40 patients, 31 of whom showed a response to the treatment. Of the clinical symptoms examined, walking ability and leg numbness were significantly improved with an average effective period of 2.5 months. However, patients with radicular pain and severely affected patients did not respond well. Nerve root circulation in eight patients who subsequently underwent surgery was measured with a laser Doppler flowmeter. We observed increased blood flow in seven of these eight patients, after the intraoperative administration of lipo-PGE1. Lipo-PGE1 produced symptomatic improvement for a limited period in the treatment of NIC associated with LSS. The drug appeared to exert its effects through an increase in the circulation of blood in the nerve roots and the cauda equina.
No takes yet. Share an insight, caveat, or question.
Murakami et al. (1997) conducted an observational in Neurogenic intermittent claudication (NIC) associated with lumbar spinal stenosis (LSS) (n=40). Intravenous Lipoprostaglandin E1 (lipo-PGE1) was evaluated on Clinical response to treatment. Intravenous lipoprostaglandin E1 produced a clinical response in 77.5% (31 of 40) of patients with neurogenic intermittent claudication, with an average effective period of 2.5 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: